In the entire landscape of psychiatric medicine, few conditions present such a stark challenge as anorexia nervosa. It has the highest mortality rate of any mental illness — not just from physical complications, but from suicide. And for decades, the treatments available have produced response rates so low that clinicians describe the condition as one of psychiatry's most intractable problems.
The core difficulty is neurological. Anorexia is not primarily a disorder of hunger or food. It is a disorder of rigid thinking — a brain locked into patterns of perfectionism, threat hypervigilance, and distorted self-perception that standard therapeutic approaches cannot easily penetrate. The architecture of the illness is the obstacle to treating the illness.
This is precisely why researchers at Imperial College London, UC San Diego, and Johns Hopkins are now studying psilocybin as a treatment candidate. Not as a nutritional intervention or an appetite modifier, but as a neurological disruptor — a compound that acts directly on the circuits that make eating disorders so hard to break.
The Serotonin Paradox at the Heart of Eating Disorders
To understand why psilocybin is being investigated for eating disorders, you first need to understand the serotonin system — and the counterintuitive way it behaves in anorexia.
Serotonin is conventionally described as a "happiness molecule." But its role is far more precise: it acts as a modulator of threat sensitivity, impulse control, and the brain's ability to update beliefs. In healthy brains, serotonin activity at the 5-HT2A receptor — the receptor that psilocybin binds — mediates cognitive flexibility, openness to new information, and the loosening of rigid mental structures.
In people with anorexia nervosa, this system is profoundly disrupted. Research by Bailer et al. (2007) demonstrated that women recovered from anorexia show persistently elevated serotonin transporter binding in the anterior cingulate cortex — a region governing conflict monitoring and error detection. More critically, 5-HT2A receptor binding is reduced in multiple cortical regions. The brain is effectively running with a suppressed serotonin flexibility system, locked in heightened threat detection and rigid rule-following.
The paradox of SSRIs in anorexia: Standard antidepressants that increase serotonin availability show poor efficacy for anorexia nervosa — possibly because the problem is not serotonin deficiency, but receptor-level dysfunction. Psilocybin, by directly activating the 5-HT2A receptor rather than flooding the synapse, bypasses this obstacle entirely.
This distinction matters enormously. SSRIs raise serotonin levels throughout the synapse but cannot overcome receptor downregulation at the cortical level. Psilocybin, as a direct 5-HT2A agonist, sidesteps this bottleneck. When psilocybin binds the 5-HT2A receptor in the prefrontal cortex and default mode network, it forces the system open — regardless of downstream serotonin availability.
How Rigid Thinking Drives Eating Disorders
Cognitive rigidity is not a secondary feature of eating disorders. It is constitutive of them. A 2014 systematic review by Lang et al., which analysed 35 studies and over 1,200 participants, found that impaired cognitive flexibility — specifically deficits in set-shifting, the ability to switch between rules or mental frameworks — is one of the most consistently replicated neuropsychological findings in anorexia, persisting even after weight restoration.
This rigidity manifests clinically as: unrelenting perfectionism that equates any deviation from dietary rules with catastrophic failure; inability to update body image perceptions despite objective evidence; hyper-focused attention on food and weight; and profound difficulty in tolerating uncertainty — a trait that also predicts poor treatment outcomes.
Standard CBT, the first-line psychological treatment for eating disorders, is built on the assumption that beliefs can be challenged through rational discussion. But when the underlying neural architecture cannot easily shift — when set-shifting is neurologically impaired — the conversation never really lands. The cognitive lock is hardware-level, not software-level.
The Inner Work Demands the Right Foundation
Intentional altered states require preparation, container, and integration. OOTW psilocybin products are formulated for those who approach this work with seriousness — and understand what the neuroplasticity window demands.
Shop OOTW Psilocybin →What Psilocybin Does to the Rigid Brain
Psilocybin's action on the eating-disordered brain is best understood through three converging mechanisms:
1. Default Mode Network Disruption
The default mode network (DMN) — anchored in the medial prefrontal cortex and posterior cingulate — is the neural substrate of self-referential thought. In eating disorders, the DMN becomes chronically over-engaged in self-evaluative loops: body monitoring, weight comparisons, rule rehearsal. Robin Carhart-Harris's neuroimaging work showed that psilocybin acutely reduces DMN activity and coherence, temporarily dissolving the rigid self-model that maintains these loops. This is not merely subjective — it is measurable on fMRI scans within thirty minutes of administration.
2. Entropic Brain Hypothesis — Increasing Neural Flexibility
Carhart-Harris and Friston's entropic brain framework proposes that psychedelics increase global brain entropy — a measure of signal complexity and unpredictability. In the rigid brain of eating disorders, neural entropy is pathologically low: the brain is running the same attractor states on repeat. Psilocybin transiently raises entropy across the cortex, allowing the brain to access configurations it cannot reach in ordinary consciousness. This is the neurological definition of openness — the precondition for therapeutic insight.
3. BDNF and Synaptic Plasticity
Beyond the acute session, psilocybin upregulates brain-derived neurotrophic factor (BDNF) and promotes dendritic spine growth in the prefrontal cortex. Research by Shao et al. (2021) found that a single dose of psilocybin produced a 10% increase in dendritic spine density in mice — persisting for at least a month. For eating disorders, where the therapeutic task is building new neural representations of body, identity, and food, this downstream plasticity window may be as important as the session itself.
The Imperial College London Pilot Trial
In 2023, Robin Carhart-Harris and colleagues at Imperial College London published the first controlled clinical data on psilocybin for anorexia nervosa. The open-label pilot enrolled ten adults with longstanding anorexia (mean illness duration: seven years) who had failed to respond to standard treatments.
Participants received two psilocybin sessions — a preparatory 10mg session and a full 25mg therapeutic session — alongside psychological support from trained therapists. Assessment used the Eating Disorder Examination Questionnaire (EDE-Q) as the primary outcome measure, with secondary measures including psychological flexibility, perfectionism, anxiety, and quality of life.
At the three-month follow-up, seven of the ten participants showed clinically meaningful reductions in EDE-Q scores. Participants also reported significant improvements in psychological flexibility (AAQ-II), reduced perfectionism (MPS subscales), and greater acceptance of their bodies. The intervention was safe — no serious adverse events were recorded, and participants described the experience as among the most meaningful of their lives.
Key qualitative finding: Multiple participants described the psilocybin experience as allowing them to observe their eating disorder "from the outside" for the first time — not as their identity, but as a pattern they had been trapped within. This shift in perspective — from being the illness to witnessing it — is the hallmark of ego dissolution therapeutics.
The researchers noted limitations: open-label design, small sample, no active comparator. But the signal was strong enough to support a larger Phase IIa randomised controlled trial, which is now underway.
The UC San Diego Evidence
Independently, Stephanie Knatz Peck and colleagues at UC San Diego are running a Phase IIa trial of psilocybin-assisted therapy for anorexia — one of several parallel investigations across North American institutions. The UCSD approach integrates psilocybin-enhanced sessions with family-based treatment principles and acceptance and commitment therapy (ACT), both of which emphasise cognitive flexibility and values-based living over rule-following.
Early reports from the UCSD cohort corroborate the Imperial findings: participants show improvements in body image flexibility, reduced weight-related obsessionality, and increased ability to engage with the interpersonal dimensions of their recovery. The illness often becomes entangled with identity and relational control; psilocybin appears to loosen this entanglement by temporarily dissolving the self-structure that the illness inhabits.
Perfectionism, Ego Dissolution, and Body Image
One of the more underappreciated dimensions of psilocybin's relevance to eating disorders is its documented effect on perfectionism. David Erritzoe and colleagues at Imperial showed in 2018 that psilocybin-assisted therapy produces lasting reductions in perfectionism scores on the Multidimensional Perfectionism Scale — persisting at twelve-month follow-up in a treatment-resistant depression cohort. Given that perfectionism is both a risk factor for and a maintaining mechanism of anorexia, this pharmacological action is clinically significant.
The mechanism appears to be ego dissolution — the temporary softening of the rigid self-construct during the psilocybin experience. The eating-disordered self is fundamentally a construction: rules, identifications, and narratives about what the body means, what thinness means, what control means. Ego dissolution does not destroy this construct, but it creates distance from it — a moment of standing outside the architecture that has felt inescapable. Research consistently shows that the depth of ego dissolution during a psilocybin session predicts the magnitude of subsequent therapeutic gains.
Challenges and Necessary Cautions
The case for psilocybin in eating disorders is scientifically compelling — but it comes with critical caveats that distinguish it from other psychiatric applications.
First, the medical frailty of individuals with severe anorexia creates safety complexities not present in depression or addiction trials. Cardiac arrhythmias, electrolyte imbalances, and low bone density can all affect session safety. The Imperial and UCSD protocols require medical stabilisation and minimum BMI thresholds before participation — conditions that exclude the most severely ill patients who may need intervention most urgently.
Second, the therapeutic relationship in eating disorder treatment is uniquely charged. Control, autonomy, and trust are central themes — and the act of voluntarily entering an altered state that involves surrendering control is not trivial. Extensive preparation, trauma-informed therapist training, and careful integration support are not optional additions; they are structural requirements for a safe and effective intervention.
Third, eating disorders are not monolithic. The mechanisms relevant to restricting anorexia differ meaningfully from those driving binge-purge behaviours in bulimia nervosa or the sensory sensitivities of ARFID. The current evidence base is almost entirely focused on anorexia; the field will need dedicated trials for each diagnostic category.
The Path Forward
What psilocybin offers eating disorder research is something genuinely novel: a compound that acts on the specific neurological features — 5-HT2A hypofunction, DMN rigidity, reduced neural entropy, impaired set-shifting — that define why these conditions are so resistant to treatment. It does not offer a cure. It offers a window: a brief period of heightened neuroplasticity and psychological openness in which the therapeutic work that ordinary CBT cannot achieve may become possible. (See also: neuroplasticity.)
Imperial College, UC San Diego, Johns Hopkins, and teams in Australia and Europe are all running or designing trials. If Phase IIa results replicate the Imperial pilot signal, Phase III trials could be in design within three years. For a condition that has resisted every pharmacological and psychological innovation thrown at it for half a century, that represents something extraordinary: a credible, evidence-based hope, built on a mechanism that psychiatry has never had access to before.